Elevating Effective Outcomes With Companion Diagnostics

By Alan Wookey

The successful development and commercialization of personalized medicines often necessitate use of companion diagnostics (CDx).

Now more than ever, drug developers need an experienced global partner to advance CDxdevelopment, who understands how to navigate the technical, regulatory and commercialization nuances to enhance the chances of program success.

Additionally, there is a sharpening focus toward smaller populations treated with drugs for orphan indications and rare diseases, umbrella clinical trials where targeted drugs are used for multiple tumor mutations, and basket clinical trials where targeted drugs focus on multiple tumor indications.

The improvements that precision medicine brings to patient outcomes are increasingly being implemented in clinical practices worldwide. Companion diagnostics are assays that are required to be used before a specific therapy can be initiated. They are often co-developed alongside a therapeutic during its clinical development journey. Extensive testing in clinical trials is required, often in multiple sites across the globe.

Companion diagnostics (CDx) is a keystone for pharma to create more precise drug therapies as personalized medicine accelerates. Here’s why a CDxcentral laboratory partner is necessary.